Finilac 50 microgram/ml oral solution for dogs and cats

Authorised

- Cabergoline

Product identification

Medicine name:
Finilac 50 microgram/ml oral solution for dogs and cats

Active substance:
Cabergoline

Target species:
Dog
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Cabergoline
50.00 microgram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Oral solution

Withdrawal period by route of administration:

Oral use:

- **Dog**
- **Cat**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QG02CB03

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Ireland

Package description:
Cardboard box containing 1 bottle (brown type-III glass, closed by a LDPE conical Luer slip syringe adapter and a HDPE screw cap) filled with 25 ml
Cardboard box containing 1 bottle (brown type-III glass, closed by a LDPE conical Luer slip syringe adapter and a HDPE screw cap) filled with 3 ml
Cardboard box containing 1 bottle (brown type-III glass, closed by a LDPE conical Luer slip syringe adapter and a HDPE screw cap) filled with 10 ml
Cardboard box containing 1 bottle (brown type-III glass, closed by a LDPE conical Luer slip syringe adapter and a HDPE screw cap) filled with 50 ml
Cardboard box containing 1 bottle (brown type-III glass, closed by a LDPE conical Luer slip syringe adapter and a HDPE screw cap) filled with 15 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Le Vet. Beheer B.V.

Marketing authorisation date:
10/07/2015

Manufacturing sites for batch release:
Dreluso Pharmazeutika Dr. Elten Und Sohn GmbH

Responsible authority:
Health Products Regulatory Authority

Authorisation number:
VPA10475/015/001

Date of authorisation status change:
10/07/2015

Reference member state:
Netherlands

Procedure number:
NL/V/0188/001

Concerned member states:
Austria Belgium Croatia Cyprus Czechia Denmark Estonia Finland France Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

---